Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Tonix Pharma ( (TNXP) ).
On December 16, 2025, Tonix Pharmaceuticals announced it has secured exclusive worldwide rights to TNX-4900, a promising non-opioid treatment for chronic neuropathic pain, from Rutgers University. This licensing agreement highlights Tonix’s strategic move to enhance its portfolio with a highly selective Sigma-1 receptor antagonist, which has shown significant efficacy and safety in preclinical models, potentially positioning the company as a leader in non-opioid pain management solutions.
The most recent analyst rating on (TNXP) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall stock score reflects a challenging financial performance with significant profitability and cash flow issues. However, recent positive corporate events and strategic developments provide a potential for future growth. The technical analysis suggests caution due to mixed signals, and the valuation is low due to ongoing losses typical in the biotech sector. The company’s proactive steps in expanding its pipeline and strategic appointments are notable positives.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative treatments for chronic conditions. The company is known for its work on non-opioid therapies, particularly in the area of neuropathic pain.
Average Trading Volume: 844,896
Technical Sentiment Signal: Sell
Current Market Cap: $227.1M
See more data about TNXP stock on TipRanks’ Stock Analysis page.